Edge Therapeutics, Inc. (EDGE) saw its loss widen to $12.17 million, or $0.42 a share for the quarter ended Mar. 31, 2017. In the previous year period, the company reported a loss of $9.17 million, or $0.32 a share. The company has not recorded any revenues for the current as well as previous quarter.
Operating loss for the quarter was $11.79 million, compared with an operating loss of $9.03 million in the previous year period.
"We began 2017 by successfully building upon the positive momentum of last year," said Brian A. Leuthner, Edge’s President and Chief Executive Officer. "Our EG-1962 Phase 3 NEWTON 2 study continues to progress in the clinic and we have activated our first site in Europe. We remain on track with our previously stated anticipated timelines for NEWTON 2 top-line efficacy data from the pre-specified interim analysis and from the full study. In addition, we initiated our study assessing EG-1962 administered directly into the basal cisterns of the brain for aneurysmal subarachnoid hemorrhage (aSAH)."
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: [email protected]
